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Résumé en
anglais
BACKGROUND & AIMS: Chronic liver diseases (CLD) are common, and are
therefore mainly managed by non-hepatologists. These physicians lack access to the
best non-invasive tests of liver fibrosis, and consequently cannot accurately
determine the disease severity. Referral to a hepatologist is then needed. We aimed
to implement an algorithm, comprising a new first-line test usable by all physicians,
for the detection of advanced liver fibrosis in all CLD patients.
METHODS: Diagnostic study: 3754 CLD patients with liver biopsy were 2:1
randomized into derivation and validation sets. Prognostic study: longitudinal follow-
up of 1275 CLD patients with baseline fibrosis tests.
RESULTS: Diagnostic study: the easy liver fibrosis test (eLIFT), an "at-a-glance" sum
of points attributed to age, gender, gamma-glutamyl transferase, aspartate
aminotransferase (AST), platelets and prothrombin time, was developed for the
diagnosis of advanced fibrosis. In the validation set, eLIFT and fibrosis-4 (FIB4) had
the same sensitivity (78.0% vs. 76.6%, p=0.470) but eLIFT gave fewer false positive
results, especially in patients ≥60years old (53.8% vs. 82.0%, p<0.001), and was
thus more suitable as screening test. FibroMeter with vibration controlled transient
elastography (VCTE) was the most accurate among the eight fibrosis tests
evaluated. The sensitivity of the eLIFT-FM algorithm (first-line eLIFT, second-line
FibroMeter) was 76.1% for advanced fibrosis and 92.1% for cirrhosis. Prognostic
study: patients diagnosed as having "no/mild fibrosis" by the algorithm had excellent
liver-related prognosis with thus no need for referral to a hepatologist.
CONCLUSION: The eLIFT-FM algorithm extends the detection of advanced liver
fibrosis to all CLD patients and reduces unnecessary referrals of patients without
significant CLD to hepatologists.
LAY SUMMARY: Blood fibrosis tests and transient elastography accurately diagnose
advanced liver fibrosis in the large population of patients having chronic liver
disease, but these non-invasive tests are only currently available in specialized
centers. We have developed an algorithm including the easy liver fibrosis test
(eLIFT), a new simple and widely available blood test. It is used as a first-line
procedure that selects at-risk patients who need further evaluation with the
FibroMeter, an accurate fibrosis test combining blood markers and transient
elastography result. This new algorithm, called the eLIFT-FM, accurately identifies
the patients with advanced chronic liver disease who need referral to a specialist,
and those with no or mild liver lesions who can remain under the care of their usual
physician.
CLINICAL TRIAL REGISTRATION: No registration (analysis of pooled data from
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